-
公开(公告)号:US20060142264A1
公开(公告)日:2006-06-29
申请号:US11359616
申请日:2006-02-23
申请人: Hidenori Funamizu , Nobuo Ishiyama , Satoru Ikegami , Tadashi Okuno , Kiyoshi Inoguchi , Ping Huang , Gilda Loew
发明人: Hidenori Funamizu , Nobuo Ishiyama , Satoru Ikegami , Tadashi Okuno , Kiyoshi Inoguchi , Ping Huang , Gilda Loew
IPC分类号: A61K31/554 , A61K31/553
CPC分类号: C07D223/16 , C07C237/22 , C07C2602/12 , C07D209/38 , C07D209/52 , C07D211/22 , C07D215/06 , C07D215/227 , C07D215/56 , C07D223/20 , C07D225/06 , C07D225/08 , C07D243/10 , C07D243/12 , C07D243/14 , C07D265/36 , C07D267/14 , C07D267/18 , C07D279/16 , C07D279/26 , C07D281/10 , C07D281/14 , C07D401/04 , C07D403/12 , C07D417/12 , C07D487/04 , C07D498/04
摘要: Compounds of structural Formula (I) where A is a lipophilic group including an aliphatic bridging group, B is a lipophilic group, D is a group having at least one amino or substituted amino group and R is hydrogen, alkyl or cycloalkyl, and pharmaceutically acceptable salts and individual isomers thereof, which have growth hormone releasing activity in humans or animals.
摘要翻译: 结构式(I)的化合物,其中A是包括脂族桥连基团的亲脂基团,B是亲脂基团,D是具有至少一个氨基或取代的氨基的基团,R是氢,烷基或环烷基,以及药学上可接受的 其盐和单独的异构体,其在人或动物中具有生长激素释放活性。
-
公开(公告)号:US07279573B2
公开(公告)日:2007-10-09
申请号:US11359616
申请日:2006-02-23
申请人: Hidenori Funamizu , Nobuo Ishiyama , Satoru Ikegami , Tadashi Okuno , Kiyoshi Inoguchi , Ping Huang , Gilda Loew
发明人: Hidenori Funamizu , Nobuo Ishiyama , Satoru Ikegami , Tadashi Okuno , Kiyoshi Inoguchi , Ping Huang , Gilda Loew
IPC分类号: A61P5/00 , A61K31/55 , C07D267/00
CPC分类号: C07D223/16 , C07C237/22 , C07C2602/12 , C07D209/38 , C07D209/52 , C07D211/22 , C07D215/06 , C07D215/227 , C07D215/56 , C07D223/20 , C07D225/06 , C07D225/08 , C07D243/10 , C07D243/12 , C07D243/14 , C07D265/36 , C07D267/14 , C07D267/18 , C07D279/16 , C07D279/26 , C07D281/10 , C07D281/14 , C07D401/04 , C07D403/12 , C07D417/12 , C07D487/04 , C07D498/04
摘要: Compounds of structural Formula (I) where A is a lipophilic group including an aliphatic bridging group, B is a lipophilic group, D is a group having at least one amino or substituted amino group and R is hydrogen, alkyl or cycloalkyl, and pharmaceutically acceptable salts and individual isomers thereof, which have growth hormone releasing activity in humans or animals
摘要翻译: 结构式(I)的化合物,其中A是包括脂族桥连基团的亲脂基团,B是亲脂基团,D是具有至少一个氨基或取代的氨基的基团,R是氢,烷基或环烷基,以及药学上可接受的 其盐和单独的异构体,其在人或动物中具有生长激素释放活性
-
公开(公告)号:US07064121B2
公开(公告)日:2006-06-20
申请号:US10962598
申请日:2004-10-13
申请人: Hidenori Funamizu , Nobuo Ishiyama , Satoru Ikegami , Tadashi Okuno , Kiyoshi Inoguchi , Ping Huang , Gilda Loew
发明人: Hidenori Funamizu , Nobuo Ishiyama , Satoru Ikegami , Tadashi Okuno , Kiyoshi Inoguchi , Ping Huang , Gilda Loew
IPC分类号: A61P19/00 , A61K31/55 , C07D267/14 , C07D267/16 , C07D281/10
CPC分类号: C07D223/16 , C07C237/22 , C07C2602/12 , C07D209/38 , C07D209/52 , C07D211/22 , C07D215/06 , C07D215/227 , C07D215/56 , C07D223/20 , C07D225/06 , C07D225/08 , C07D243/10 , C07D243/12 , C07D243/14 , C07D265/36 , C07D267/14 , C07D267/18 , C07D279/16 , C07D279/26 , C07D281/10 , C07D281/14 , C07D401/04 , C07D403/12 , C07D417/12 , C07D487/04 , C07D498/04
摘要: Compounds of structural Formula (I) where A is a lipophilic group including an aliphatic bridging group, B is a lipophilic group, D is a group having at least one amino or substituted amino group and R is hydrogen, alkyl or cycloalkyl, and pharmaceutically acceptable salts and individual isomers thereof, which have growth hormone releasing activity in humans or animals
摘要翻译: 结构式(I)的化合物,其中A是包括脂族桥连基团的亲脂基团,B是亲脂基团,D是具有至少一个氨基或取代的氨基的基团,R是氢,烷基或环烷基,以及药学上可接受的 其盐和单独的异构体,其在人或动物中具有生长激素释放活性
-
公开(公告)号:US20050059699A1
公开(公告)日:2005-03-17
申请号:US10962598
申请日:2004-10-13
申请人: Hidenori Funamizu , Nobuo Ishiyama , Satoru Ikegami , Tadashi Okuno , Kiyoshi Inoguchi , Ping Huang , Gilda Loew
发明人: Hidenori Funamizu , Nobuo Ishiyama , Satoru Ikegami , Tadashi Okuno , Kiyoshi Inoguchi , Ping Huang , Gilda Loew
IPC分类号: C07D243/12 , A61K31/395 , A61K31/403 , A61K31/404 , A61K31/47 , A61K31/535 , A61K31/538 , A61K31/5383 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5517 , A61K31/553 , A61K31/554 , A61K38/00 , A61P5/06 , A61P17/02 , A61P19/00 , A61P19/08 , A61P19/10 , A61P37/00 , A61P43/00 , C07D209/38 , C07D209/42 , C07D215/06 , C07D215/22 , C07D223/16 , C07D223/20 , C07D225/06 , C07D225/08 , C07D243/24 , C07D265/36 , C07D267/14 , C07D267/20 , C07D279/16 , C07D281/10 , C07D403/12 , C07D417/12 , C07D487/04 , C07D498/04 , C07K5/06 , C07D211/60 , A61K31/401 , A61K31/445
CPC分类号: C07D223/16 , C07C237/22 , C07C2602/12 , C07D209/38 , C07D209/52 , C07D211/22 , C07D215/06 , C07D215/227 , C07D215/56 , C07D223/20 , C07D225/06 , C07D225/08 , C07D243/10 , C07D243/12 , C07D243/14 , C07D265/36 , C07D267/14 , C07D267/18 , C07D279/16 , C07D279/26 , C07D281/10 , C07D281/14 , C07D401/04 , C07D403/12 , C07D417/12 , C07D487/04 , C07D498/04
摘要: Compounds of structural Formula (I) where A is a lipophilic group including an aliphatic bridging group, B is a lipophilic group, D is a group having at least one amino or substituted amino group and R is hydrogen, alkyl or cycloalkyl, and pharmaceutically acceptable salts and individual isomers thereof, which have growth hormone releasing activity in humans or animals.
摘要翻译: 结构式(I)的化合物,其中A是包括脂族桥连基团的亲脂基团,B是亲脂基团,D是具有至少一个氨基或取代的氨基的基团,R是氢,烷基或环烷基,以及药学上可接受的 其盐和单独的异构体,其在人或动物中具有生长激素释放活性。
-
公开(公告)号:US06864250B1
公开(公告)日:2005-03-08
申请号:US09485845
申请日:1998-08-20
申请人: Hidenori Funamizu , Nobuo Ishiyama , Satoru Ikegami , Tadashi Okuno , Kiyoshi Inoguchi , Ping Huang , Gilda Loew
发明人: Hidenori Funamizu , Nobuo Ishiyama , Satoru Ikegami , Tadashi Okuno , Kiyoshi Inoguchi , Ping Huang , Gilda Loew
IPC分类号: C07D243/12 , A61K31/395 , A61K31/403 , A61K31/404 , A61K31/47 , A61K31/535 , A61K31/538 , A61K31/5383 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5517 , A61K31/553 , A61K31/554 , A61K38/00 , A61P5/06 , A61P17/02 , A61P19/00 , A61P19/08 , A61P19/10 , A61P37/00 , A61P43/00 , C07D209/38 , C07D209/42 , C07D215/06 , C07D215/22 , C07D223/16 , C07D223/20 , C07D225/06 , C07D225/08 , C07D243/24 , C07D265/36 , C07D267/14 , C07D267/20 , C07D279/16 , C07D281/10 , C07D403/12 , C07D417/12 , C07D487/04 , C07D498/04 , C07K5/06 , C07D267/02 , C07D281/02
CPC分类号: C07D223/16 , C07C237/22 , C07C2602/12 , C07D209/38 , C07D209/52 , C07D211/22 , C07D215/06 , C07D215/227 , C07D215/56 , C07D223/20 , C07D225/06 , C07D225/08 , C07D243/10 , C07D243/12 , C07D243/14 , C07D265/36 , C07D267/14 , C07D267/18 , C07D279/16 , C07D279/26 , C07D281/10 , C07D281/14 , C07D401/04 , C07D403/12 , C07D417/12 , C07D487/04 , C07D498/04
摘要: Compounds of structural Formula (I) where A is a lipophilic group including an aliphatic bridging group, B is a lipophilic group, D is a group having at least one amino or substituted amino group and R is hydrogen, alkyl or cycloalkyl, and pharmaceutically acceptable salts and individual isomers thereof, which have growth hormone releasing activity in humans or animals
摘要翻译: 结构式(I)的化合物,其中A是包括脂族桥连基团的亲脂基团,B是亲脂基团,D是具有至少一个氨基或取代的氨基的基团,R是氢,烷基或环烷基,以及药学上可接受的 其盐和单独的异构体,其在人或动物中具有生长激素释放活性
-
公开(公告)号:US20060014701A1
公开(公告)日:2006-01-19
申请号:US11218562
申请日:2005-09-06
申请人: Nobuo Ishiyama , Hirohide Ishige , Mitsuo Mimura , Tadashi Okuno , Kiyoharu Ukai , Takeshi Kiyofuji , Shinji Tauchi , Kiyoshi Inoguchi , Ping Huang , Gilda Loew , Linda Maki
发明人: Nobuo Ishiyama , Hirohide Ishige , Mitsuo Mimura , Tadashi Okuno , Kiyoharu Ukai , Takeshi Kiyofuji , Shinji Tauchi , Kiyoshi Inoguchi , Ping Huang , Gilda Loew , Linda Maki
CPC分类号: C07K5/06165 , A61K38/00 , C07K5/0202 , C07K5/0205 , C07K5/06026 , C07K5/06034 , C07K5/06078 , C07K5/06139
摘要: Disclosed are the novel compounds as growth hormone secretagogues represented by the structural Formula I: wherein R1 is, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, or substituted or unsubstituted amino, X is —CO— or —SO2—, Y is: wherein n is an integer from 0-4, R4 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, R5 and R6 are independently selected from hydrogen, substituted or unsubstituted alkyl, or R5 and R6 or R4 and R5 are taken together to form substituted or unsubstituted alkylene, R2 is hydrogen, or substituted or unsubstituted alkyl, R3 is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, D is substituted or unsubstituted amino, substituted or unsubstituted alkoxy, or substituted or unsubstituted alkylthio, * represents an asymmetric center, and pharmaceutically acceptable salts and individual isomers thereof, which have growth hormone releasing activity in humans or animals.
摘要翻译: 公开了由结构式I表示的生长激素促分泌素的新化合物:其中R 1是取代或未取代的烷基,取代或未取代的环烷基,取代或未取代的烷氧基,取代或未取代的芳基或取代的 或未取代的氨基,X是-CO-或-SO 2 - ,Y是:其中n是0-4的整数,R 4是氢,取代或未取代的 烷基,取代或未取代的环烷基,取代或未取代的芳基,R 5和R 6独立地选自氢,取代或未取代的烷基或R 5, R S和R 6或R 4和R 5一起形成取代或未取代的亚烷基,R 2 O, >是氢或取代或未取代的烷基,R 3是取代或未取代的烷基,取代或未取代的环烷基,取代或未取代的芳基,D是取代或未取代的 取代或未取代的烷氧基,或取代或未取代的烷硫基,*表示在人或动物中具有生长激素释放活性的不对称中心及其药学上可接受的盐和各异构体。
-
7.
公开(公告)号:US20060274794A1
公开(公告)日:2006-12-07
申请号:US11436817
申请日:2006-05-18
CPC分类号: H01S3/0014 , A61B2018/00636 , B23K26/03 , B23K26/032 , B23K26/034 , B23K26/707 , B23K2103/30 , B23K2103/50 , G06F19/00 , G16H40/40 , H01S3/0007 , H01S3/0602 , H01S3/0941 , H01S3/13 , H01S3/1643
摘要: A problem diagnosis method and problem repair method for a laser device such as laser treatment devices used in the medical field and laser processing devices used in industrial fields, capable of detecting problems in laser devices early and reducing the time required for maintenance work on the laser devices are provided. The method comprises a step of measuring the intensity of scattered light generated by an optical part inside the laser device; a step of referring to data indicating a temporal change in the scattered light predicted under predetermined operating conditions of the laser device, and predicting the seriousness of the problem from the intensity of scattered light; and a step of determining what kind of maintenance work is necessary based on the seriousness of the problem. Additionally, the seriousness of the problem in the optical part can be predicted by executing fuzzy logic based on membership functions defining the relationship between scattered light intensity and the seriousness of problems of optical parts.
摘要翻译: 用于医疗领域中使用的激光治疗装置的激光装置的问题诊断方法和问题修复方法以及在工业领域中使用的激光加工装置,能够及早检测激光装置中的问题,并减少激光器的维护工作所需的时间 提供设备。 该方法包括测量由激光装置内部的光学部件产生的散射光的强度的步骤; 参考指示在激光装置的预定操作条件下预测的散射光的时间变化的数据的步骤,并且根据散射光的强度预测问题的严重性; 并根据问题的严重性确定必要的维修工作。 另外,可以通过基于限定散射光强度与光学部件问题严重性之间的关系的隶属函数执行模糊逻辑来预测光学部件中的问题的严重性。
-
公开(公告)号:US07457030B2
公开(公告)日:2008-11-25
申请号:US10597717
申请日:2005-02-04
申请人: Tadashi Okuno , Akira Watanabe
发明人: Tadashi Okuno , Akira Watanabe
CPC分类号: G02F1/3544 , G02F2001/3546
摘要: The energy conversion efficiency from light that is to be converted to converted light of a wavelength conversion device is adjusted so as always to be kept stably at a maximum. The wavelength conversion device is provided with a laser light source 10 for generating a fundamental wave light, a nonlinear optical crystal 16 into which the fundamental wave light is made to enter to generate converted light, and an optical path adjusting portion 30 for adjusting the direction of propagation of the fundamental wave light and the position of the light beam of the fundamental wave light in order to make the fundamental wave light enter the nonlinear optical crystal 16 while satisfying phase matching conditions. The optical path adjusting portion 30 is constituted so as to be provided with a first reflecting mirror 12 and a second reflecting mirror 14, and the first reflecting mirror is provided with adjustment means driven by motors M1 and M2, and the second reflecting mirror is provided with adjustment means driven by motors M3 and M4. Additionally, the wavelength conversion device is provided with a semi-transparent mirror 18 for splitting off and taking out one portion of output light 17, and a photodetector 22 for detecting this split off output light. An electrical signal 23 that is output from the photodetector 22 is input into an adjustment value calculating means 26, and in this adjustment value calculating means, the necessary adjustment values for the adjustment means in the optical path adjusting portion 30 are calculated using fuzzy inference, and this result is output to an optical path adjusting portion control device 28. The optical path adjusting portion control device 28 carries out adjustment of the optical path based upon output signals 27 from the adjustment value calculating means 26.
摘要翻译: 调整要转换为波长转换装置的转换光的光的能量转换效率,使得始终保持稳定地最大化。 波长转换装置设置有用于产生基波光的激光光源10,使基波光进入其中以产生转换光的非线性光学晶体16,以及用于调节方向的光路调节部30 基波的传播和基波光的位置,以使基波进入非线性光学晶体16同时满足相位匹配条件。 光路调整部30构成为设有第一反射镜12和第二反射镜14,第一反射镜设置有由电动机M 1,M 2驱动的调节装置,第二反射镜 设置有由电动机M 3和M 4驱动的调节装置。另外,波长转换装置设置有用于分离和取出一部分输出光17的半透明反射镜18和用于检测该分离的光电检测器22 关闭输出光。 从光电检测器22输出的电信号23输入到调整值计算单元26中,在该调整值计算单元中,使用模糊推理来计算光路调整单元30中的调整单元所需的调整值, 并将该结果输出到光路调整部控制装置28.光路调整部控制装置28基于来自调整值计算装置26的输出信号27进行光路的调整。
-
9.
公开(公告)号:US07689369B2
公开(公告)日:2010-03-30
申请号:US11436817
申请日:2006-05-18
CPC分类号: H01S3/0014 , A61B2018/00636 , B23K26/03 , B23K26/032 , B23K26/034 , B23K26/707 , B23K2103/30 , B23K2103/50 , G06F19/00 , G16H40/40 , H01S3/0007 , H01S3/0602 , H01S3/0941 , H01S3/13 , H01S3/1643
摘要: A problem diagnosis method and problem repair method for a laser device are provided. The method includes measuring the intensity of scattered light generated by an optical part inside the laser device; referring to data indicating a temporal change in the scattered light predicted under predetermined operating conditions of the laser device, and predicting the seriousness of the problem from the intensity of scattered light; and determining what kind of maintenance work is necessary based on the seriousness of the problem. Additionally, the seriousness of the problem in the optical part can be predicted by executing fuzzy logic based on membership functions defining the relationship between scattered light intensity and the seriousness of problems of optical parts.
摘要翻译: 提供了一种用于激光装置的问题诊断方法和问题修复方法。 该方法包括测量由激光装置内部的光学部件产生的散射光的强度; 参照表示在激光装置的预定操作条件下预测的散射光的时间变化的数据,并根据散射光的强度预测问题的严重性; 并根据问题的严重性确定需要什么样的维护工作。 另外,可以通过基于限定散射光强度与光学部件问题严重性之间的关系的隶属函数执行模糊逻辑来预测光学部件中的问题的严重性。
-
公开(公告)号:US20080175282A1
公开(公告)日:2008-07-24
申请号:US10597717
申请日:2005-02-04
申请人: Tadashi Okuno , Akira Watanabe
发明人: Tadashi Okuno , Akira Watanabe
IPC分类号: H01S3/10
CPC分类号: G02F1/3544 , G02F2001/3546
摘要: The energy conversion efficiency from light that is to be converted to converted light of a wavelength conversion device is adjusted so as always to be kept stably at a maximum. The wavelength conversion device is provided with a laser light source 10 for generating a fundamental wave light, a nonlinear optical crystal 16 into which the fundamental wave light is made to enter to generate converted light, and an optical path adjusting portion 30 for adjusting the direction of propagation of the fundamental wave light and the position of the light beam of the fundamental wave light in order to make the fundamental wave light enter the nonlinear optical crystal 16 while satisfying phase matching conditions. The optical path adjusting portion 30 is constituted so as to be provided with a first reflecting mirror 12 and a second reflecting mirror 14, and the first reflecting mirror is provided with adjustment means driven by motors M1 and M2, and the second reflecting mirror is provided with adjustment means driven by motors M3 and M4. Additionally, the wavelength conversion device is provided with a semi-transparent mirror 18 for splitting off and taking out one portion of output light 17, and a photodetector 22 for detecting this split off output light. An electrical signal 23 that is output from the photodetector 22 is input into an adjustment value calculating means 26, and in this adjustment value calculating means, the necessary adjustment values for the adjustment means in the optical path adjusting portion 30 are calculated using fuzzy inference, and this result is output to an optical path adjusting portion control device 28. The optical path adjusting portion control device 28 carries out adjustment of the optical path based upon output signals 27 from the adjustment value calculating means 26.
摘要翻译: 调整要转换为波长转换装置的转换光的光的能量转换效率,使得始终保持稳定地最大化。 波长转换装置设置有用于产生基波光的激光光源10,使基波光进入其中以产生转换光的非线性光学晶体16,以及用于调节方向的光路调节部30 基波的传播和基波光的位置,以使基波进入非线性光学晶体16同时满足相位匹配条件。 光路调整部30构成为设有第一反射镜12和第二反射镜14,第一反射镜设置有由电动机M 1,M 2驱动的调节装置,第二反射镜 设置有由电动机M 3和M 4驱动的调节装置。另外,波长转换装置设置有用于分离和取出一部分输出光17的半透明反射镜18和用于检测该分离的光电检测器22 关闭输出光。 从光电检测器22输出的电信号23输入到调整值计算单元26中,在该调整值计算单元中,使用模糊推理来计算光路调整单元30中的调整单元所需的调整值, 并将该结果输出到光路调整部控制装置28.光路调整部控制装置28基于来自调整值计算装置26的输出信号27进行光路的调整。
-
-
-
-
-
-
-
-
-